{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T21:34:56Z","timestamp":1789940096889,"version":"4.0.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,5,7]],"date-time":"2018-05-07T00:00:00Z","timestamp":1525651200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s10928-018-9592-y","type":"journal-article","created":{"date-parts":[[2018,5,7]],"date-time":"2018-05-07T07:46:09Z","timestamp":1525679169000},"page":"505-522","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Population pharmacokinetics and exposure\u2013response modeling and simulation for evolocumab in healthy volunteers and patients with hypercholesterolemia"],"prefix":"10.1007","volume":"45","author":[{"given":"Mita","family":"Kuchimanchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Grover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice G.","family":"Emery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ransi","family":"Somaratne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott M.","family":"Wasserman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Gibbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Doshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,7]]},"reference":[{"key":"9592_CR1","doi-asserted-by":"publisher","unstructured":"Cholesterol Treatment Trialists (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376(9753):1670\u20131681. \n                    https:\/\/doi.org\/10.1016\/s0140-6736(10)61350-5","DOI":"10.1016\/s0140-6736(10)61350-5"},{"issue":"4","key":"9592_CR2","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1161\/ATVBAHA.108.179564","volume":"29","author":"JL Goldstein","year":"2009","unstructured":"Goldstein JL, Brown MS (2009) The LDL receptor. Arterioscler Thromb Vasc Biol 29(4):431\u2013438. \n                    https:\/\/doi.org\/10.1161\/ATVBAHA.108.179564","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"9592_CR3","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1097\/MOL.0000000000000114","volume":"25","author":"TA Lagace","year":"2014","unstructured":"Lagace TA (2014) PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells. Curr Opin Lipidol 25(5):387\u2013393. \n                    https:\/\/doi.org\/10.1097\/MOL.0000000000000114","journal-title":"Curr Opin Lipidol"},{"issue":"18","key":"9592_CR4","doi-asserted-by":"publisher","first-page":"11649","DOI":"10.1074\/jbc.M114.611988","volume":"290","author":"R Romagnuolo","year":"2015","unstructured":"Romagnuolo R, Scipione CA, Boffa MB, Marcovina SM, Seidah NG, Koschinsky ML (2015) Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin\/kexin type 9 through the low density lipoprotein receptor. J Biol Chem 290(18):11649\u201311662. \n                    https:\/\/doi.org\/10.1074\/jbc.M114.611988","journal-title":"J Biol Chem"},{"issue":"2","key":"9592_CR5","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1194\/jlr.M700437-JLR200","volume":"49","author":"HE Careskey","year":"2008","unstructured":"Careskey HE, Davis RA, Alborn WE, Troutt JS, Cao G, Konrad RJ (2008) Atorvastatin increases human serum levels of proprotein convertase subtilisin\/kexin type 9. J Lipid Res 49(2):394\u2013398. \n                    https:\/\/doi.org\/10.1194\/jlr.M700437-JLR200","journal-title":"J Lipid Res"},{"issue":"8","key":"9592_CR6","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1161\/01.ATV.0000134621.14315.43","volume":"24","author":"G Dubuc","year":"2004","unstructured":"Dubuc G, Chamberland A, Wassef H, Davignon J, Seidah NG, Bernier L, Prat A (2004) Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 24(8):1454\u20131459. \n                    https:\/\/doi.org\/10.1161\/01.ATV.0000134621.14315.43","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"9592_CR7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1476-511X-7-22","volume":"7","author":"J Mayne","year":"2008","unstructured":"Mayne J, Dewpura T, Raymond A, Cousins M, Chaplin A, Lahey KA, Lahaye SA, Mbikay M, Ooi TC, Chretien M (2008) Plasma PCSK9 levels are significantly modified by statins and fibrates in humans. Lipids Health Dis 7:22. \n                    https:\/\/doi.org\/10.1186\/1476-511X-7-22","journal-title":"Lipids Health Dis"},{"issue":"Suppl","key":"9592_CR8","doi-asserted-by":"publisher","first-page":"S172","DOI":"10.1194\/jlr.R800091-JLR200","volume":"50","author":"JD Horton","year":"2009","unstructured":"Horton JD, Cohen JC, Hobbs HH (2009) PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res 50(Suppl):S172\u2013177. \n                    https:\/\/doi.org\/10.1194\/jlr.R800091-JLR200","journal-title":"J Lipid Res"},{"issue":"24","key":"9592_CR9","doi-asserted-by":"publisher","first-page":"9820","DOI":"10.1073\/pnas.0903849106","volume":"106","author":"JC Chan","year":"2009","unstructured":"Chan JC, Piper DE, Cao Q, Liu D, King C, Wang W, Tang J, Liu Q, Higbee J, Xia Z, Di Y, Shetterly S, Arimura Z, Salomonis H, Romanow WG, Thibault ST, Zhang R, Cao P, Yang XP, Yu T, Lu M, Retter MW, Kwon G, Henne K, Pan O, Tsai MM, Fuchslocher B, Yang E, Zhou L, Lee KJ, Daris M, Sheng J, Wang Y, Shen WD, Yeh WC, Emery M, Walker NP, Shan B, Schwarz M, Jackson SM (2009) A proprotein convertase subtilisin\/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci U S A 106(24):9820\u20139825. \n                    https:\/\/doi.org\/10.1073\/pnas.0903849106","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9592_CR10","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.2147\/DDDT.S67498","volume":"9","author":"AF Cicero","year":"2015","unstructured":"Cicero AF, Colletti A, Borghi C (2015) Profile of evolocumab and its potential in the treatment of hyperlipidemia. Drug Des Devel Ther 9:3073\u20133082. \n                    https:\/\/doi.org\/10.2147\/dddt.s67498","journal-title":"Drug Des Devel Ther"},{"issue":"19","key":"9592_CR11","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.jacc.2012.08.986","volume":"60","author":"CS Dias","year":"2012","unstructured":"Dias CS, Shaywitz AJ, Wasserman SM, Smith BP, Gao B, Stolman DS, Crispino CP, Smirnakis KV, Emery MG, Colbert A, Gibbs JP, Retter MW, Cooke BP, Uy ST, Matson M, Stein EA (2012) Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. J Am Coll Cardiol 60(19):1888\u20131898. \n                    https:\/\/doi.org\/10.1016\/j.jacc.2012.08.986","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"9592_CR12","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1002\/jcph.840","volume":"57","author":"JP Gibbs","year":"2017","unstructured":"Gibbs JP, Doshi S, Kuchimanchi M, Grover A, Emery MG, Dodds MG, Gibbs MA, Somaratne R, Wasserman SM, Blom D (2017) Impact of target-mediated elimination on the dose and regimen of evolocumab, a human monoclonal antibody against proprotein convertase subtilisin\/kexin type 9 (PCSK9). J Clin Pharmacol 57(5):616\u2013626. \n                    https:\/\/doi.org\/10.1002\/jcph.840","journal-title":"J Clin Pharmacol"},{"issue":"19","key":"9592_CR13","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","volume":"370","author":"DJ Blom","year":"2014","unstructured":"Blom DJ, Hala T, Bolognese M, Lillestol MJ, Toth PD, Burgess L, Ceska R, Roth E, Koren MJ, Ballantyne CM, Monsalvo ML, Tsirtsonis K, Kim JB, Scott R, Wasserman SM, Stein EA, DESCARTES Investigators (2014) A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 370(19):1809\u20131819. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1316222","journal-title":"N Engl J Med"},{"issue":"8","key":"9592_CR14","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1161\/CIRCRESAHA.115.307071","volume":"117","author":"DJ Blom","year":"2015","unstructured":"Blom DJ, Djedjos CS, Monsalvo ML, Bridges I, Wasserman SM, Scott R, Roth E (2015) Effects of evolocumab on vitamin E and steroid hormone levels: results from the 52-week, phase 3, double-blind, randomized, placebo-controlled DESCARTES study. Circ Res 117(8):731\u2013741.\u00a0\n                    https:\/\/doi.org\/10.1161\/circresaha.115.307071","journal-title":"Circ Res"},{"issue":"9858","key":"9592_CR15","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1016\/S0140-6736(12)61770-X","volume":"380","author":"RP Giugliano","year":"2012","unstructured":"Giugliano RP, Desai NR, Kohli P, Rogers WJ, Somaratne R, Huang F, Liu T, Mohanavelu S, Hoffman EB, McDonald ST, Abrahamsen TE, Wasserman SM, Scott R, Sabatine MS, LAPLACE-TIMI 57 Investigators (2012) Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet 380(9858):2007\u20132017. \n                    https:\/\/doi.org\/10.1016\/s0140-6736(12)61770-x","journal-title":"Lancet"},{"issue":"23","key":"9592_CR16","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1016\/j.jacc.2014.03.018","volume":"63","author":"MJ Koren","year":"2014","unstructured":"Koren MJ, Lundqvist P, Bolognese M, Neutel JM, Monsalvo ML, Yang J, Kim JB, Scott R, Wasserman SM, Bays H, MENDEL-2 Investigators (2014) Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol 63(23):2531\u20132540. \n                    https:\/\/doi.org\/10.1016\/j.jacc.2014.03.018","journal-title":"J Am Coll Cardiol"},{"issue":"9858","key":"9592_CR17","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1016\/S0140-6736(12)61771-1","volume":"380","author":"MJ Koren","year":"2012","unstructured":"Koren MJ, Scott R, Kim JB, Knusel B, Liu T, Lei L, Bolognese M, Wasserman SM (2012) Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet 380(9858):1995\u20132006. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(12)61771-1","journal-title":"Lancet"},{"issue":"20","key":"9592_CR18","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.112.144055","volume":"126","author":"F Raal","year":"2012","unstructured":"Raal F, Scott R, Somaratne R, Bridges I, Li G, Wasserman SM, Stein EA (2012) Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation 126(20):2408\u20132417. \n                    https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.112.144055","journal-title":"Circulation"},{"issue":"9965","key":"9592_CR19","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","volume":"385","author":"FJ Raal","year":"2015","unstructured":"Raal FJ, Honarpour N, Blom DJ, Hovingh GK, Xu F, Scott R, Wasserman SM, Stein EA, TESLA Investigators (2015) Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet 385(9965):341\u2013350. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(14)61374-X","journal-title":"Lancet"},{"issue":"18","key":"9592_CR20","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1001\/jama.2014.4030","volume":"311","author":"JG Robinson","year":"2014","unstructured":"Robinson JG, Nedergaard BS, Rogers WJ, Fialkow J, Neutel JM, Ramstad D, Somaratne R, Legg JC, Nelson P, Scott R, Wasserman SM, Weiss R, LAPLACE-2 Investigators (2014) Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA 311(18):1870\u20131882. \n                    https:\/\/doi.org\/10.1001\/jama.2014.4030","journal-title":"JAMA"},{"issue":"33","key":"9592_CR21","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1093\/eurheartj\/ehu085","volume":"35","author":"EA Stein","year":"2014","unstructured":"Stein EA, Giugliano RP, Koren MJ, Raal FJ, Roth EM, Weiss R, Sullivan D, Wasserman SM, Somaratne R, Kim JB, Yang J, Liu T, Albizem M, Scott R, Sabatine MS, PROFICIO\u00a0Investigators (2014) Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. Eur Heart J 35(33):2249\u20132259. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehu085","journal-title":"Eur Heart J"},{"issue":"23","key":"9592_CR22","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","volume":"63","author":"E Stroes","year":"2014","unstructured":"Stroes E, Colquhoun D, Sullivan D, Civeira F, Rosenson RS, Watts GF, Bruckert E, Cho L, Dent R, Knusel B, Xue A, Scott R, Wasserman SM, Rocco M, GAUSS-2 Investigators (2014) Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol 63(23):2541\u20132548. \n                    https:\/\/doi.org\/10.1016\/j.jacc.2014.03.019","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"9592_CR23","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1001\/jama.2012.25790","volume":"308","author":"D Sullivan","year":"2012","unstructured":"Sullivan D, Olsson AG, Scott R, Kim JB, Xue A, Gebski V, Wasserman SM, Stein EA (2012) Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA 308(23):2497\u20132506. \n                    https:\/\/doi.org\/10.1001\/jama.2012.25790","journal-title":"JAMA"},{"key":"9592_CR24","volume-title":"NONMEM user\u2019s guides (1989-2009)","author":"S Beal","year":"2009","unstructured":"Beal S, Sheiner LB, Boeckmann A, Bauer RJ (2009) NONMEM user\u2019s guides (1989-2009). Icon Development Solutions, Ellicott City MD"},{"issue":"5","key":"9592_CR25","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s10928-008-9102-8","volume":"35","author":"L Gibiansky","year":"2008","unstructured":"Gibiansky L, Gibiansky E, Kakkar T, Ma P (2008) Approximations of the target-mediated drug disposition model and identifiability of model parameters. J Pharmacokinet Pharmacodyn 35(5):573\u2013591. \n                    https:\/\/doi.org\/10.1007\/s10928-008-9102-8","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"9592_CR26","unstructured":"Bauer RJ (2011) NONMEM users guide: introduction to NONMEM 7.2.0. Icon Development Solutions, Ellicott City"},{"issue":"4","key":"9592_CR27","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s10928-008-9094-4","volume":"35","author":"JE Ahn","year":"2008","unstructured":"Ahn JE, Karlsson MO, Dunne A, Ludden TM (2008) Likelihood based approaches to handling data below the quantification limit using NONMEM VI. J Pharmacokinet Pharmacodyn 35(4):401\u2013421. \n                    https:\/\/doi.org\/10.1007\/s10928-008-9094-4","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"5","key":"9592_CR28","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1023\/A:1012299115260","volume":"28","author":"SL Beal","year":"2001","unstructured":"Beal SL (2001) Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 28(5):481\u2013504","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"1","key":"9592_CR29","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s10928-007-9078-9","volume":"35","author":"W Byon","year":"2008","unstructured":"Byon W, Fletcher CV, Brundage RC (2008) Impact of censoring data below an arbitrary quantification limit on structural model misspecification. J Pharmacokinet Pharmacodyn 35(1):101\u2013116. \n                    https:\/\/doi.org\/10.1007\/s10928-007-9078-9","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"9592_CR30","unstructured":"Gastonguay MR (2004) A full model estimation approach for covariate effects: inference based on clinical importance and estimation precision. AAPS J 6(Suppl1):Abstract W4354"},{"issue":"12","key":"9592_CR31","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1111\/bcp.13403","volume":"83","author":"L O\u2019Brien","year":"2017","unstructured":"O\u2019Brien L, Westwood P, Gao L, Heathman M (2017) Population pharmacokinetic meta-analysis of ramucirumab in cancer patients. Br J Clin Pharmacol 83(12):2741\u20132751. \n                    https:\/\/doi.org\/10.1111\/bcp.13403","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"9592_CR32","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/psp4.12139","volume":"6","author":"M Ahamadi","year":"2017","unstructured":"Ahamadi M, Freshwater T, Prohn M, Li CH, de Alwis DP, de Greef R, Elassaiss-Schaap J, Kondic A, Stone JA (2017) Model-based characterization of the pharmacokinetics of pembrolizumab: a humanized anti-PD-1 monoclonal antibody in advanced solid tumors. CPT Pharmacometrics Syst Pharmacol 6(1):49\u201357. \n                    https:\/\/doi.org\/10.1002\/psp4.12139","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"5","key":"9592_CR33","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/jcph.1063","volume":"58","author":"Z Yao","year":"2018","unstructured":"Yao Z, Hu C, Zhu Y, Xu Z, Randazzo B, Wasfi Y, Chen Y, Sharma A, Zhou H (2018) Population pharmacokinetic modeling of guselkumab, a human IgG1\u03bb monoclonal antibody targeting IL-23, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol \u00a058(5):613\u2013627.\u00a0\n                    https:\/\/doi.org\/10.1002\/jcph.1063","journal-title":"J Clin Pharmacol"},{"key":"9592_CR34","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-017-0620-7","author":"S Kasichayanula","year":"2018","unstructured":"Kasichayanula S, Grover A, Emery MG, Gibbs MA, Somaratne R, Wasserman SM, Gibbs JP (2018) Clinical pharmacokinetics and pharmacodynamics of evolocumab, a PCSK9 inhibitor. Clin Pharmacokinet. \n                    https:\/\/doi.org\/10.1007\/s40262-017-0620-7","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"9592_CR35","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/S2213-8587(17)30313-3","volume":"5","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Leiter LA, Wiviott SD, Giugliano RP, Deedwania P, De Ferrari GM, Murphy SA, Kuder JF, Gouni-Berthold I, Lewis BS, Handelsman Y, Pineda AL, Honarpour N, Keech AC, Sever PS, Pedersen TR (2017) Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol 5(12):941\u2013950. \n                    https:\/\/doi.org\/10.1016\/S2213-8587(17)30313-3","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"9592_CR36","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S2213-8587(16)00003-6","volume":"4","author":"N Sattar","year":"2016","unstructured":"Sattar N, Preiss D, Robinson JG, Djedjos CS, Elliott M, Somaratne R, Wasserman SM, Raal FJ (2016) Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data. Lancet Diabetes Endocrinol 4(5):403\u2013410. \n                    https:\/\/doi.org\/10.1016\/S2213-8587(16)00003-6","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"9592_CR37","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.amjcard.2017.07.047","volume":"120","author":"N Sattar","year":"2017","unstructured":"Sattar N, Toth PP, Blom DJ, Koren MJ, Soran H, Uhart M, Elliott M, Cyrille M, Somaratne R, Preiss D (2017) Effect of the proprotein convertase subtilisin\/kexin type 9 inhibitor evolocumab on glycemia, body weight, and new-onset diabetes mellitus. Am J Cardiol 120(9):1521\u20131527. \n                    https:\/\/doi.org\/10.1016\/j.amjcard.2017.07.047","journal-title":"Am J Cardiol"},{"issue":"12","key":"9592_CR38","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1194\/jlr.R026658","volume":"53","author":"G Lambert","year":"2012","unstructured":"Lambert G, Sjouke B, Choque B, Kastelein JJ, Hovingh GK (2012) The PCSK9 decade. J Lipid Res 53(12):2515\u20132524. \n                    https:\/\/doi.org\/10.1194\/jlr.R026658","journal-title":"J Lipid Res"},{"issue":"1","key":"9592_CR39","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/sj.clpt.6100241","volume":"82","author":"MO Karlsson","year":"2007","unstructured":"Karlsson MO, Savic RM (2007) Diagnosing model diagnostics. Clin Pharmacol Ther 82(1):17\u201320. \n                    https:\/\/doi.org\/10.1038\/sj.clpt.6100241","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"9592_CR40","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.cmpb.2012.08.009","volume":"109","author":"TT Bergsma","year":"2013","unstructured":"Bergsma TT, Knebel W, Fisher J, Gillespie WR, Riggs MM, Gibiansky L, Gastonguay MR (2013) Facilitating pharmacometric workflow with the metrumrg package for R. Comput Methods Programs Biomed 109(1):77\u201385. \n                    https:\/\/doi.org\/10.1016\/j.cmpb.2012.08.009","journal-title":"Comput Methods Programs Biomed"},{"issue":"3","key":"9592_CR41","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/clpt.2011.149","volume":"90","author":"D Menon-Andersen","year":"2011","unstructured":"Menon-Andersen D, Yu B, Madabushi R, Bhattaram V, Hao W, Uppoor RS, Mehta M, Lesko L, Temple R, Stockbridge N, Laughren T, Gobburu JV (2011) Essential pharmacokinetic information for drug dosage decisions: a concise visual presentation in the drug label. Clin Pharmacol Ther 90(3):471\u2013474. \n                    https:\/\/doi.org\/10.1038\/clpt.2011.149","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"9592_CR42","doi-asserted-by":"publisher","first-page":"633","DOI":"10.2165\/11535960-000000000-00000","volume":"49","author":"NL Dirks","year":"2010","unstructured":"Dirks NL, Meibohm B (2010) Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 49(10):633\u2013659. \n                    https:\/\/doi.org\/10.2165\/11535960-000000000-00000","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"9592_CR43","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1177\/0091270004272731","volume":"45","author":"YN Sun","year":"2005","unstructured":"Sun YN, Lu JF, Joshi A, Compton P, Kwon P, Bruno RA (2005) Population pharmacokinetics of efalizumab (humanized monoclonal anti-CD11a antibody) following long-term subcutaneous weekly dosing in psoriasis subjects. J Clin Pharmacol 45(4):468\u2013476. \n                    https:\/\/doi.org\/10.1177\/0091270004272731","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"9592_CR44","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1177\/0091270009339192","volume":"49","author":"Z Xu","year":"2009","unstructured":"Xu Z, Vu T, Lee H, Hu C, Ling J, Yan H, Baker D, Beutler A, Pendley C, Wagner C, Davis HM, Zhou H (2009) Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-alpha human monoclonal antibody, in patients with psoriatic arthritis. J Clin Pharmacol 49(9):1056\u20131070. \n                    https:\/\/doi.org\/10.1177\/0091270009339192","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"9592_CR45","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1177\/0091270008329556","volume":"49","author":"Y Zhu","year":"2009","unstructured":"Zhu Y, Hu C, Lu M, Liao S, Marini JC, Yohrling J, Yeilding N, Davis HM, Zhou H (2009) Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12\/23p40, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol 49(2):162\u2013175. \n                    https:\/\/doi.org\/10.1177\/0091270008329556","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"9592_CR46","doi-asserted-by":"publisher","first-page":"73","DOI":"10.4331\/wjbc.v3.i4.73","volume":"3","author":"Y Vugmeyster","year":"2012","unstructured":"Vugmeyster Y, Xu X, Theil FP, Khawli LA, Leach MW (2012) Pharmacokinetics and toxicology of therapeutic proteins: advances and challenges. World J Biol Chem 3(4):73\u201392. \n                    https:\/\/doi.org\/10.4331\/wjbc.v3.i4.73","journal-title":"World J Biol Chem"},{"issue":"5","key":"9592_CR47","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/clpt.2008.170","volume":"84","author":"W Wang","year":"2008","unstructured":"Wang W, Wang EQ, Balthasar JP (2008) Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 84(5):548\u2013558. \n                    https:\/\/doi.org\/10.1038\/clpt.2008.170","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"9592_CR48","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.2165\/11599820-000000000-00000","volume":"51","author":"A Chakraborty","year":"2012","unstructured":"Chakraborty A, Tannenbaum S, Rordorf C, Lowe PJ, Floch D, Gram H, Roy S (2012) Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1\u03b2 monoclonal antibody. Clin Pharmacokinet 51(6):e1\u2013e18. \n                    https:\/\/doi.org\/10.2165\/11599820-000000000-00000","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"9592_CR49","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1023\/A:1020917122093","volume":"27","author":"RJ Bauer","year":"1999","unstructured":"Bauer RJ, Dedrick RL, White ML, Murray MJ, Garovoy MR (1999) Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis. J Pharmacokinet Biopharm 27(4):397\u2013420","journal-title":"J Pharmacokinet Biopharm"},{"issue":"5","key":"9592_CR50","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1111\/j.1365-2125.2006.02803.x","volume":"63","author":"N Hayashi","year":"2007","unstructured":"Hayashi N, Tsukamoto Y, Sallas WM, Lowe PJ (2007) A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Br J Clin Pharmacol 63(5):548\u2013561. \n                    https:\/\/doi.org\/10.1111\/j.1365-2125.2006.02803.x","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"9592_CR51","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1067\/mcp.2001.114887","volume":"69","author":"JM Kovarik","year":"2001","unstructured":"Kovarik JM, Nashan B, Neuhaus P, Clavien PA, Gerbeau C, Hall ML, Korn A (2001) A population pharmacokinetic screen to identify demographic-clinical covariates of basiliximab in liver transplantation. Clin Pharmacol Ther 69(4):201\u2013209","journal-title":"Clin Pharmacol Ther"},{"key":"9592_CR52","unstructured":"Mondick JT, Gibiansky L, Gastonguay MR, Veal GJ, Barrett JS (2006) Acknowledging parameter uncertainty in the simulation-based design of an actinomycin-D pharmacokinetic study in pediatric patients with Wilms\u2019 tumor or rhabdomyosarcoma. Paper presented at the 15th Meeting of Population Approach Group Europe, Brugge\/Bruges, Belgium, June 14\u201316"}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10928-018-9592-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-018-9592-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-018-9592-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,9]],"date-time":"2019-05-09T13:09:03Z","timestamp":1557407343000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10928-018-9592-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,7]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["9592"],"URL":"https:\/\/doi.org\/10.1007\/s10928-018-9592-y","relation":{},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"value":"1567-567X","type":"print"},{"value":"1573-8744","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,7]]},"assertion":[{"value":"20 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"M. Kuchimanchi, S.M. Wasserman, and S. Doshi are employees of and stockholders in Amgen Inc. R. Somaratne and J.P. Gibbs are identified as inventors on at least one pending patent application owned by Amgen Inc. relating to evolocumab. S.M. Wasserman appears on a number of pending patents owned by Amgen Inc. relating to evolocumab and PCSK9 inhibition. J.P. Gibbs, A. Grover, and M.G. Emery were employees of and stockholders in Amgen at the time this work was completed. J.P. Gibbs is currently employed by AbbVie, Inc. A. Grover is currently employed by BioMarin Pharmaceutical Inc. M.G. Emery is currently employed by Seattle Genetics.\u00a0R. Somaratne is a stockholder of Amgen, was employed by Amgen at the time this work was completed, and is currently employed by NGM Biopharmaceuticals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All studies were conducted in accordance with principles for human experimentation as defined in the Declaration of Helsinki and International Conference on Harmonization Good Clinical Practice guidelines, and approved by the relevant institutional review boards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from each study participant after they were told of the potential risks and benefits as well as the investigational nature of the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}